----
Current ValuationThe current P/E ratio is -0.77, within the reasonable range, cheaper than 39.85% of the time in the past 1 years, and the industry ranks 74/173, the industry Median -0.95.
-0.774xP/E
$8.74Stock price
$-11.30Earnings per share
-0.774xP/E
Stock price$8.74Earnings per share$-11.30
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -2.51x
- Typical range
- -4.80x–-0.47x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
012243648
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BAXUSBaxter | -11.85x | 141.71% | $12.59B |
GKOSUSGlaukos | -50.69x | 75.37% | $9.53B |
TFXUSTeleflex | -5.12x | 118.39% | $5.29B |
PLSEUSPulse Biosciences | -44.32x | 27.55% | $3.55B |
IRTCUSIRhythm | -253.36x | 70.88% | $3.53B |
BFLYUSButterfly Network | -30.95x | 34.41% | $2.32B |
AXGNUSAxogen | -63.50x | 18.38% | $2.13B |
ASSTUSStrive | -2.11x | 63.23% | $2.06B |
NVCRUSNovocure | -11.73x | 1.23% | $1.74B |
ATECUSAlphatec | -14.80x | 41.67% | $1.63B |
KMTSUSKestra Medical Tech | -10.60x | 0.94% | $1.59B |
DRTSUSAlpha Tau Medical | -14.44x | -- | $1.34B |
TNDMUSTandem Diabetes | -17.76x | 77.60% | $1.12B |
AORTUSArtivion | -333.70x | 266.67% | $1.06B |
ENOVUSEnovis | -0.95x | 100.97% | $1.05B |
IARTUSIntegra LifeSciences | -143.14x | 109.42% | $1.04B |
PRCTUSPROCEPT BioRobotics | -9.14x | 3.47% | $1.00B |
BBNXUSBeta Bionics | -13.44x | 13.22% | $980.72M |
CBLLUSCeribell | -14.15x | 35.15% | $934.12M |
SIBNUSSI-BONE | -59.88x | 8.85% | $876.20M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
